ViolaWeijiaZhuMDPhD

Oncology • Worcester, MA

Thoracic Cancer

Associate Clinical Professor of Medicine

Join to view full profile

Dr. Zhu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zhu's full profile

Already have an account?

Office
55 Lake Ave N
Worcester, MA 01655
Phone+1 508-334-3550

Education & Training

Boston University Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Hackensack University Medical Center/Englewood Hospital and Medical CenterResidency, Internal Medicine, 2009 - 2011
Shanghai Medical UniversityClass of 2000

Certifications & Licensure

CA State Medical License 2014 - 2026
MA State Medical License 2010 - 2026
NY State Medical License 2016 - 2025
NJ State Medical License 2009 - 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

3 citations
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.
Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia
Cancer Discovery. 2024-12-02
12 citations
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.
Alexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou
Cancer Discovery. 2023-03-01
10 citations
The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study.
David J Benjamin, Shuai Chen, Joanna B Eldredge, Shiruyeh Schokrpur, Debory Li
JTO Clinical and Research Reports. 2022-12-01

Journal Articles

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
Lori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine
Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK+ Non-Small Cell Lung Cancer: A Histological Analysis
Viola Zhu, MD, Clinical Lung Cancer

Authored Content

Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020

Press Mentions

OncLive® Hosts the Latest State of the Science Summit™ on Non-Small Cell Lung CancerApril 29th, 2019

Other Languages

Chinese (Mandarin)